Index

Note: Page numbers in *italics* refer to figures; page numbers in *bold* refer to tables; page numbers suffixed with b refer to boxes.

A
AAG (*α*-acid glycoprotein)
  fetal levels, 56, 58
  maternal levels, 54, 56
abdomen, magnetic resonance imaging of fetal anomalies, 99
abdominal wall defects, neonatal, management, 359
abortions, spontaneous, anesthetic-related, 142, 143
abruption, placental, 308
acardiac twin, fetal intervention, 177–178
accelerations, fetal heart rate, 106, 110
acid–base balance
  fetal physiology, 114
  following cesarean delivery, general vs. regional anesthesia, 230–231
neonatal assessments and prediction of outcome, 129–131
during normal labor, 116, 117
acid–base equilibrium effect, placental drug transfer, 56–58, 57
acid–base monitoring
  fetal see fetal acid–base monitoring
  neonatal, prediction of outcome and, 129–131
acidemia, fetal see fetal acidemia
acute fetal hypoxemia
  fetal responses, 36, 44–45
  see also fetal hypoxia
adenosine triphosphate (ATP), 114, 115
adipose tissue, brown, 10
adrenals, development, 5
advanced life support, maternal resuscitation, 336, 338
aerobic metabolism, fetal, 114, 115
airway clearance, maternal resuscitation, 336
airway management
  general anesthesia, complications, 286, 288–289
  maternal resuscitation, 336, 338
  neonatal resuscitation, 354
  pregnant trauma patients, 330–331
airway pressure release ventilation (APRV), 331
albumin
  fetal levels, 56, 58
  maternal levels, 54, 56
alcohol
  fetal exposure, effects, 202–203
  maternal abuse, 14, 166, 170
  withdrawal, symptoms and treatment, 168
alfentanil, 151
  attenuation of stress response to laryngoscopy/tracheal intubation, 240, 240
  maternal abuse, 14, 166, 170
  withdrawal, symptoms and treatment, 168
alpha-fetoprotein, 56
Amiel–Tison neurologic assessment at term (ATNAT), 133
γ-aminobutyrate see GABA
amnioinfusion, 349
amniotic bands, 9
amniotic fluid dynamics, 43
amphetamines
  maternal abuse, 166, 169
  withdrawal, symptoms and treatment, 168
anaerobic metabolism, fetal, 114, 115
analgesia
  fetal, 174
  labor see labor analgesia
  neuraxial see neuraxial analgesia/anesthesia
anaphylaxis, maternal, 289
anemia
dilutional, 22, 39
fetal, Doppler ultrasound evaluation, 36
anencephaly, 8, 91
anesthesia
  EXIT procedure, 185–186
  for fetal distress see fetal distress anesthesia for fetal/neonatal effects see anesthesia, fetal/neonatal effects
  fetal surgery, 174
general see general anesthesia
maternal complications see maternal anesthetic complications
neuraxial see neuraxial analgesia/anesthesia
physiologic changes of pregnancy and, 158
substance-abusing parturients and, 170
anesthesia, fetal/neonatal effects, 218–231
developmental see fetal development, effect of anesthetic drugs
general anesthesia see general anesthesia, fetal/neonatal effects
of maternal blood pressure control see maternal blood pressure control, fetal effects
potentially beneficial effects, 220–221
regional anesthesia see neuraxial analgesia/anesthesia, fetal/neonatal effects
anesthesia-induced developmental neuroapoptosis, 158–159, 192–197, 200–206, 219
activation mechanism, 193–194
alcohol-induced neuroapoptosis and, 202–203
animal behavioral studies, 195–196, 201
augmentation by drug combinations, 203–204
caffeine and, 203–204
evidence from animal studies, 200–201, 204–205
extrapolation of animal findings to humans, 196, 205
fundamentals of, 201–202
future perspectives, 196–197
human epidemiological studies, 205–206
mechanism, 193
natural programmed cell death and, 202
non-human primate studies, 201, 204–205
prevention, 194–195, 206
window of vulnerability, 201
anesthetic agent exposure
assisted reproduction techniques see assisted reproduction techniques, anesthetic/analgesic drug exposure
early pregnancy see early pregnancy, anesthetic/analgesic drug exposure
non-obstetric surgery, effect on developing fetus see fetal development, effect of anesthetic drugs
occupational see occupational exposure, inhalational anesthetics
anesthetic agents, pharmacokinetics maternal drug distribution, 54
maternal–placental–fetal distribution, 56, 57
placental metabolism, 56
placental transfer, 55
see also placental drug transfer, factors influencing studies, 59, 59
aneuploidy, screening, 89–91
animal studies
anesthetic-induced neuroapoptosis, 195–196, 200–201, 204–205
exposure to anesthetics during pregnancy, 144, 159
fetal distress, effects of anesthesia, 318
antenatal maternal complications twin gestation, 298
see also maternal complications antiemetic agents, effect on assisted reproduction techniques and early pregnancy, 153
antihypertensive therapy, pregnant women, 304–305
antipyretic prophylaxis, epidural-related fever, 282
aortic isthmus, 34, 41, 42
aortocaval compression, 118
avoidance, 237, 252
posture and, 252
Apger score, 67–68, 75–76, 131
early vs. late initiation of neuraxial labor analgesia, 274, 274
following cesarean delivery, general vs. regional anesthesia, 222, 226–228, 229
maternal positioning during neuraxial anesthesia and, 253, 254, 255, 256, 257
neonatal outcomes and, 131, 316
systemic vs. neuraxial labor analgesia, 266–267
apoptosis
anesthesia-induced in developing brain see anesthesia-induced developmental neuroapoptosis biomarkers, 193
neurodevelopment and, 192, 202
apoptosome, 193
APRV (airway pressure release ventilation), 331
Arnold–Chiari malformation, 93
arterial blood pressure see maternal blood pressure
arterial spin labelling (ASL), 102
asphyxia, fetal see fetal asphyxia assisted reproduction techniques (ART), 147, 148
assisted reproduction techniques, anesthetic/analgesic drug exposure, 148–153
benzodiazepines, 151–152
local anesthetic agents, 149, 151
nitrous oxide, 152
non-steroidal anti-inflammatory agents, 152
opioids, 151
propofol, 152
thiopental, 152
volatile halogenated agents, 152–153
asymmetric intrauterine growth restriction, 10, 12
ataxic cerebral palsy, 130
see also cerebral palsy
ATNAT (Amiel–Tison neurologic assessment at term), 133
atosiban, 348
ATP (adenosine triphosphate), 114, 115
arterial blood pressure
see maternal blood pressure
aseptia, choanal, 358
autonomy, 365
maternal, fetal beneficence and, 365–372, 376
respect for, 375
B
bag–mask ventilation
maternal resuscitation, 336
neonatal resuscitation, 354
base deficit (BD), 116, 316
baseline fetal heart rate, 105
pathophysiology, 109–110
see also fetal heart rate
basic life support, maternal resuscitation, 335–338, 336
Bax, 193, 202
Bcl-2, 192, 193, 195
behavior, fetal see fetal behavior beneficence
fetal, maternal autonomy and, 365–372, 376
principle of, 365, 374–375
benzodiazepines
effect on assisted reproduction techniques and early pregnancy, 151–152
effect on fetal development, 157, 157, 161
BH3-only proteins, 193
biophysical profile score (BPS), 47–48, 48, 50
INDEX

birth
   physiologic changes following see postnatal adaptations
preterm see preterm birth
blastocyst, 3, 7
blastomere, 3
blood
   fetal see fetal blood
   maternal see maternal blood
blood flow
   fetal see fetal blood flow
   placental, 27, 32, 55
   see also umbilical blood flow;
   uterine blood flow;
   uteroplacental circulation
blood-oxygen-level-dependent (BOLD) functional MRI, 101
blood pressure see maternal blood pressure
BNBAS (Brazelton neonatal behavioral assessment), 133
body stalk anomaly, 91
Bohr effect, 25, 26, 114
BOLD fMRI (blood-oxygen-level-dependent functional magnetic resonance imaging), 101
blood pressure see maternal blood pressure
BPS (biophysical profile score), 47–48, 48, 50
bradycardia, fetal see fetal bradycardia
brain-derived neurotrophic factor (BDNF), 192
anesthesia-induced developmental neuroapoptosis and, 194
brain development, 6, 98, 149
effect of anesthetic drugs, 149, 150, 158–159, 219
see also anesthesia-induced developmental neuroapoptosis
see also neurodevelopment
brain, fetal see fetal brain
Brazelton neonatal behavioral assessment (BNBAS), 133
breastfeeding
   effect of anesthesia for cesarean delivery, 230
effects of labor analgesia early vs. late initiation of neuraxial analgesia, 273, 275
   systemic vs. neuraxial analgesia, 268
breath, first, 64–65
see also neonatal breathing
breathing
   fetal, 64, 65
   neonatal see neonatal breathing
   periodic, 66
   brown adipose tissue, 10
C
   caffeine, anesthesia-induced developmental neuroapoptosis and, 203–204
   Canada, forced medical intervention law, 366–367
cannabis see marijuana (cannabis)
caput succedaneum, effect on fetal pulse oximetry readings, 125
carbon dioxide, placental exchange, 24, 25, 26
   carbon monoxide, 12
cardiac arrest, maternal, 335, 336, 337
   see also maternal resuscitation
cardiac defects see congenital heart defects
cardiac output
   blood pressure vs., 238
   parturition-associated changes, 22
   pregnancy-associated changes, 19–20
cardiomyopathy, peripartum, 307
cardiopulmonary complications, preeclampsia, 306–307
cardio-respiratory assessment, neonatal, 67–69
   see also Apgar score
cardiocotography (CTG), 44, 116
   assessment of degree of urgency of cesarean delivery, 317
cardiovascular changes, maternal, 19–22, 39, 158, 329
   cardiac output, 19–20
   heart structure, 20
   hematologic system, 22
   parturition-associated, 22
   peripheral resistance and arterial blood pressure, 20–21
   plasma volume expansion, 21–22
   venous structure/function, 21
   cardiovascular system
   maternal adaptations see cardiovascular changes, maternal
   neonatal adaptation, 67
carotid body reflex, 66
caspases, 193, 202
CDH see congenital diaphragmatic hernia (CDH)
central nervous system (CNS)
   fetal abnormalities
   effect on fetal behaviors, 43
   magnetic resonance imaging, 97–99
    local anesthetic toxicity, 290
    see also entries beginning brain
cerebral palsy, 119, 119, 129
cerebrovascular accident (CVA), prevention, 304
cerebrovascular regulation, fetal, 36
cesarean delivery
   anesthesia, fetal/neonatal effects, 217–231
   general anesthesia see general anesthesia, fetal/neonatal effects
   of maternal blood pressure control see maternal blood pressure control, fetal effects
   regional anesthesia see neuraxial analgesia/anesthesia, fetal/neonatal effects
   assessment of degree of urgency, 317
   classification of urgency, 287, 288, 316–317, 316b
elective see elective cesarean delivery
   emergency see emergency cesarean delivery
   EXIT procedure vs., 184, 184
   maternal oxygen supplementation during see maternal oxygen administration
   maternal position see cesarean delivery, maternal position
   neonatal outcome
   effect of maternal oxygen administration, 246, 247
   effect of maternal position, 253, 254, 255
   general vs. regional anesthesia, 222, 226–228
   perimortem see perimortem cesarean delivery
   postmortem, 288
   preeclamptic women, regional anesthesia, 310–311
INDEX

384  
scheduled, 288  
trauma patients, 331–332  
see also perimortem cesarean delivery  
urgent, 288  
fetal indication see urgent cesarean delivery, fetal indication  
cesarean delivery, fetal/neonatal effects, 217–231  
general anestheisa see general anestheisa, fetal/neonatal effects  
maternal position see cesarean delivery, maternal position  
reduced expulsion of fetal lung water, 217–218  
regional anestheisa see neuraxial anestheisa/anesthesia, fetal/neonatal effects  
uterine incision, 217  
ketogenic delivery, maternal position, 251–257  
neuraxial anestheisa, 252–257  
epidural anestheisa, 257  
necrotic outcome and, 253, 254, 255, 256–257  
spinal anestheisa, 253, 254, 255, 256–257  
pourest and aortocaval compression, 252  
chest compressions  
maternal resuscitation, 336–337  
necrotic resuscitation, 355–356  
chest radiographs, pregnancy-associated changes, 20  
choanal atresia, 358  
chioroamnionitis, epidural-related fever and, 281  
chiorionic villi, 32  
formation, 4  
chioronic fetal hyoxia, 48–49  
fetal responses, 36, 48–49  
see also fetal hyoxia  
cigarette smoking, 12, 14, 169  
see also tobacco  
circle of Willis, 36  
circulation  
fetal see fetal circulation  
necrotic see necrotic circulation  
uteroplacental see uteroplacental circulation  
circulatory centralization, fetal response to hyoxia, 45, 49, 286–287  
cleft lip/palate, fetal imaging, 99  
clinical monitoring, fetal see fetal monitoring  
clinical practice, transition from research, maternal–fetal research ethics, 378–379  
clinical risk index for babies (CRIB), 131, 132  
clinical trials  
fetal pulse oximetry, 126–127  
maternal–fetal research ethics, 378  
clinimetric tools, 75–76  
see also Apgar score  
clonidine, developmental effects, 161  
clotting factors, pregnancy-associated changes, 22  
“cobbers,” epidural-related fever management, 282, 282  
cocaine  
maternal abuse, 166, 170  
withdrawal, symptoms and treatment, 168  
colloid osmotic pressure (COP), changes in preeclampsia, 303  
color, neonatal assessment, 68  
combined spinal–epidural (CSE) anestheisa/anesthesia  
fetal effects, 321  
acid–base status, 231  
fetal pulse oximetry readings, 126, 127  
see also neuraxial anestheisa/anesthesia, fetal/neonatal effects  
maternal positioning during cesarean delivery, 253, 254, 255, 256–257  
see also epidural anestheisa/anesthesia; spinal anestheisa/anesthesia  
competency, legal in pregnancy, 369–372  
complications  
EXIT procedure, 189  
fetal see fetal complications  
maternal see maternal complications  
necrotic see necrotic complications  
twin gestation see twins, complications  
concurrent validity, 79  
congenital anomalies, 3  
fetal interventions see fetal surgical interventions  
necrotic emergencies, 357–359  
see also fetal anomalies; specific abnormalities  
congenital cystic adenomatoid malformations (CCAMs), 178  
fetal interventions, 178  
congenital diaphragmatic hernia (CDH), 7, 175, 358  
fetal surgery, 175–176, 176  
magnetic resonance imaging, 99–100  
necrotic management, 358  
congenital heart defects  
fetal interventions, 179  
necrotic management, 358–359  
prenatal screening, 92–93  
conjoined twins, 299  
consent, informed, 369, 377  
construct validity, 79  
content validity, 79  
contraction stress test (CST), 44  
CRIB (clinical risk index for babies), 131, 132  
criterion validity, 79  
CTG see cardiotocography (CTG)  
cycliclity, fetal behavior, 42  
cytochrome P450  
fetal pharmacokinetics, 58  
maternal pharmacokinetics, 54  
placental, 56  
cytomegalovirus (CMV), 12  
cytorochoblast, 3, 4  
D  
Dandy Walker malformation, 93  
dantrolene, 289  
death, maternal, 288  
decelerations see fetal heart rate decelerations  
Declaration of Helsinki, 377  
defibrillation, maternal resuscitation, 337–338  
delivery, twins, 300–301  
dependent moral status, fetus, 376  
development  
early, 3–4, 4  
fetal see fetal development
neural see neurodevelopment
periods of teratogen vulnerability, 3, 4, 156
developmental outcome, maternal exposure to inhalational anesthetics, 143
dexmedetomidine
  effect on fetal development, 161
  neuroprotective effects, 195
diagnostic imaging
  magnetic resonance imaging (MRI); ultrasonography
  obstetric anesthesia, 148–153
  anesthetic/analgesic drug exposure, 149–150
  maternal blood pressure control, 238–239
  elective cesarean delivery vs., 288
  maternal blood pressure control, 238–239
  emergency cesarean delivery
  elective cesarean delivery vs., 288
  maternal blood pressure control, 238–239
  trauma patients, 331–332
  neonatal resuscitation, 345–354
  see also tracheal intubation
  endpoints, surrogate see surrogate endpoints

neurodevelopmental impact, 149, 150
nitrous oxide, 152
non-steroidal anti-inflammatory agents, 152
opioids, 151
propofol, 152
specific considerations, 149
thiopental, 152
volatile halogenated agents, 152–153
eclampsia, 303, 309
ectoderm, 7
ECV see external cephalic version (ECV)
edema, pulmonary, preeclampsia-associated, 306–307, 308
effective renal plasma flow (ERPF), pregnancy-associated changes, 22
elective cesarean delivery, 288
  emergency cesarean delivery vs., maternal blood pressure control, 238–239
see also cesarean delivery
  elective cesarean delivery vs., maternal blood pressure control, 238–239
  trauma patients, 331–332
  see also cesarean delivery
electrocardiograms, pregnancy-associated changes, 20
electronic fetal monitoring (EFM), 104
see also fetal heart rate monitoring
embryogenesis, 3–4
embryonic pole, 3
emergencies, neonatal see neonatal emergencies
emergency cesarean delivery, 288, 316
elective cesarean delivery vs., maternal blood pressure control, 238–239
trauma patients, 331–332
see also cesarean delivery
encephalopathy, hypoxic ischemic see hypoxic ischemic encephalopathy (HIE)
endoderm, 7
endometrial gland secretions, early development, 3–4
endotracheal tubes
elective cesarean delivery, 354
  neonatal resuscitation, 354
  see also tracheal intubation
  endpoints, surrogate see surrogate endpoints
environmental exposure, anesthetic agents see occupational exposure, inhalational anesthetics
ephedrine, regional anesthesia for cesarean delivery and, 237–238, 238, 239
physiological changes in uteroplacental circulation, 316
systemic vs. neuraxial labor analgesia, 266, 267
see also fetal hypoxia
fetal distress, anesthesia for, 317–321
animal studies, 318
choice of method, 317–318
clinical studies, 318–319, 321
effects of, 318
guidelines, 320, 321
safety and timing, 317–318
fetal endotracheal occlusion (FETO), 175–176, 176
fetal exposure
anesthetic agents see fetal development, effect of anesthetic drugs ionizing radiation, 332
fetal factors
fetal oxygenation abnormalities, 44
intrauterine growth restriction, 14–15
fetal growth, 9–10
assessment, 9–10, 10, 11
determinants, 12–15, 13, 14
fetal factors, 14–15
maternal factors, 12, 14
placental factors, 14
long-term effects of alterations, 15–16
macrosomia, 15
restriction see intrauterine growth restriction (IUGR)
fetal heart rate (FHR)
fetal heart rate variability, 44–45
response to acute fetal hypoxia, 44–45
sinusoidal pattern, 111
variability see fetal heart rate variability
fetal heart rate decelerations, 106, 108, 109
early, 106, 108, 110
interventions, 112
late, 45, 46, 106, 108, 110–111
pathophysiology, 110–111
prolonged, 106, 108
variable, 45, 46, 106, 108, 110
fetal heart rate monitoring, 44, 49, 104–113, 123, 124
ancillary fetal testing, 112
characteristics and definitions, 105–106
clinical management based on FHR interpretation, 111–112
external, 104–105
history, 104
indications for clinical interventions, 112
internal, 104, 105
limitations of continuous monitoring, 113
methods, 104–105
tocodynamometry and, 109
tracings categories, 45, 47, 104, 105, 106
fetal heart rate variability, 44–45, 105–106
pathophysiology, 110
types, 105–106, 107
fetal hemoglobin, 24, 25, 42, 114
oxygen dissociation curve, 25, 26, 114
fetal hydronephrosis, 7–8, 92
fetal hypoxemia responses, 36
acute hypoxemia, 36, 44–45
see also fetal hypoxia, responses see also fetal hypoxia
fetal hypoxia acute, 44–45
assessment, 36, 115
see also fetal acid–base monitoring
causes, 43–44, 118–119, 286
chronic see chronic fetal hypoxia physiologic, 42
prediction of abnormal fetal outcome, 119, 119
fetal hypoxia, responses, 36, 44–49, 286–287
acute fetal hypoxemia, 36, 44–45
amniotic fluid dynamics, 43
biophysical scores, 47–48, 48
chronic fetal hypoxia, 36, 48–49
circulatory centralization, 45, 48, 286–287
clinical monitoring, 49
Doppler assessment, 45–46
fetal interventions
maternal–fetal research ethics, 377–379
surgical see fetal surgical interventions
fetal lipid peroxidation, effect of maternal oxygen administration, 246, 248
fetal liver
blood supply, 35, 41
development, 6
drug-metabolizing enzymes, 58
fetal lungs
blood flow regulation, 35
development, 5
lung fluid, 63
fetal magnetic resonance imaging, 97–101, 98
alternative techniques, 100–101
fetal anomalies, 97–99
fetal organ volumetry, 99–100
future perspectives, 102
fetal malformations see fetal anomalies
fetal monitoring, 50
acid–base balance see fetal acid–base monitoring
EXIT procedure, 187
heart rate see fetal heart rate monitoring
intrapartum, 50, 82, 116, 118
pulse oximetry see fetal pulse oximetry
see also fetal magnetic resonance imaging; fetal ultrasound screening; measurement
fetal organs
blood flow regulation, 35–36
MRI volumetry, 99–100
see also organogenesis; specific organs
fetal outcome
cesarean delivery, general vs. regional anesthesia, 222, 226–228
maternal trauma, 328
fetal oxygenation, 27, 42
effect of changes in uterine blood flow, 27–28
effect of supplemental maternal oxygen, 29–30, 245–246
effect of umbilical blood flow restriction, 28–29
fetal oxygenation abnormalities causes, 43–44
fetal responses see fetal hypoxia, responses
see also fetal hypoxia
fetal oxygen delivery, 24, 25, 28, 29, 345–346
factors reducing, 346–347
measures to restore, 347–349, 348
see also fetal resuscitation
see also fetal oxygenation
fetal oxygen uptake, 25, 26, 27, 27
fetal pain, 174–175
fetal pharmacokinetics, 58
study considerations, 59, 59
fetal physiology, 41–42
acid–base balance, 114
maternal trauma and, 329–330
pain, 174–175
respiratory gas exchange, 114
fetal position, early vs. late labor analgesia, 272, 274
fetal pulse oximetry, 123–127, 124
accuracy and critical threshold, 125
clinical trials, 126–127
factors affecting measurements, 125–126
instrumentation, 124–125
physiological considerations, 123–124
fetal resuscitation, 317, 345–350
application, 349–350
guidelines, 346b
indications, 346
maternal oxygen administration, 349
maternal position, 348
measures to restore oxygen delivery, 347–349, 348
tocolysis, 348
see also urgent cesarean delivery, fetal indication
fetal rights, 368, 376
fetal salvage
perimortem cesarean delivery for, 340
see also fetal resuscitation
fetal scalp blood sampling, 50, 112, 118, 119
clinical guidelines, 120
fetal surgical interventions, 3, 7–9, 173–179
amniotic bands, 9
anesthetic management, 174
congenital cardiac anomalies, 179
congenital cystic adenomatoid malformations, 178
congenital diaphragmatic hernia, 7, 175–176, 176
EXIT procedure see EXIT (ex utero intrapartum therapy) procedure
fetal pain, 174–175
future perspectives, 179
hydronephrosis, 8
indications, 174
minimally invasive, 173–174
neural tube defects, 8–9, 178
open procedures, 173
preoperative MRI, 99
sacroccygeal teratoma, 8, 178
twin reversed arterial perfusion, 177–178
twin–twin transfusion syndrome, 9, 177, 177
urinary tract obstruction, 176–177
fetal surveillance see fetal monitoring
tetal tachycardia, 103, 109–110
maternal pyrexia and, 279
fetal ultrasound screening, 89–93
aneuploidy, 89–91
diagnosis of fetal abnormalities, 91–93
see also Doppler ultrasound evaluation
fetal viability, ethical and legal aspects, 368, 376
α-fetoprotein, 56
fetoscopy, 173–174
fetus
acid–base monitoring see fetal acid–base monitoring
analgesia/anesthesia, 174
anemia, Doppler ultrasound evaluation, 36
anomalies see fetal anomalies
asphyxia see fetal asphyxia
behavior see fetal behavior
beneficence, maternal autonomy and, 365–372, 376
blood see fetal blood
bradycardia see fetal bradycardia
brain see fetal brain
circulation see fetal circulation
complications see fetal complications
consequences of maternal hyperthermia, 279, 279–280
see also epidural-related fever
development see fetal development
distress see fetal distress
duty of care, 369
effects of anesthesia see anesthesia, fetal/neonatal effects
ethical and legal challenges, 365–366, 367–369, 376
growth see fetal growth
hair, effect on fetal pulse oximetry readings, 125
heart rate see fetal heart rate (FHR)
heat loss, 278, 279
hormones, 14–15
hydronephrosis, 7–8
hypoxia see fetal hypoxia
lipid peroxidation, effect of maternal oxygen administration, 246, 248
liver see fetal liver
lungs see fetal lungs
magnetic resonance imaging see fetal magnetic resonance imaging
management during EXIT procedure, 187, 188
monitoring see fetal monitoring
organs see fetal organs
outcomes see fetal outcome
oxygenation see fetal oxygenation
oxygen delivery see fetal oxygen delivery
oxygen uptake, 25, 26, 27, 27
pain, 174–175
as patient, ethical concept, 375–376
pharmacokinetics see fetal pharmacokinetics
physiology see fetal physiology
position, early vs. late labor analgesia, 272, 274
pulse oximetry see fetal pulse oximetry
resuscitation see fetal resuscitation rights, 368, 376
salvage, perimortem cesarean delivery for, 340
scalp blood sampling see fetal scalp blood sampling
skin temperature, 279
stimulation, 112
surgery see fetal surgical interventions
tachycardia see fetal tachycardia
ultrasound screening see fetal ultrasound screening
viability, ethical and legal aspects, 368, 376
fever, maternal see maternal pyrexia
Finnegan score, 134, 135
first breath, 64–65
see also neonatal breathing
first trimester
anesthetic/analgesic drug exposure see early pregnancy, anesthetic/analgesic drug exposure
surgery in, 147–148
ultrasound screening see fetal ultrasound screening
fluid resuscitation
pregnant trauma patients, 331
see also intravenous fluid administration
focused abdominal sonography for trauma (FAST), 332
foramen ovale, 32, 33, 33, 41, 41
closure, 34
preferential streaming of ductus venous blood flow, 45, 48, 286
forced medical intervention, 366–367
functional residual capacity (FRC), establishment of, 63–64
G
GABA (γ-aminobutyrate)
receptors, anesthesia-induced developmental neuroapoptosis and, 193, 194, 200
role in neurodevelopment, 149
gamete intrafallopian transfer (GIFT), 147
gas exchange see respiratory gas exchange
gastrointestinal complications, preeclampsia, 305, 305, 305–306, 306
gastrointestinal tract, development, 6
gastrochisis, neonatal management, 359
gastrolultrication, 5
general anesthesia
complications of inadequate airway management, 286, 288–289
see also maternal anesthetic complications
hypotension during, 240
light, implications, 239–240
preeclamptic women, 311
urgent cesarean delivery for fetal distress, 317, 318, 319, 321
see also inhalational anesthetics; intravenous anesthetic agents; specific anesthetic agents
general anesthesia, fetal/neonatal effects, 218–219, 311
direct effects, 218–219
fetal response to asphyxia, 219
indirect effects, 219
inhalational anesthetics, 218
intravenous induction agents, 218
light anesthesia, 239–240
maternal blood pressure control and, 239–241
neurotoxic effects, 219
see also anesthesia-induced developmental neuroapoptosis
potentially beneficial effects, 221
regional anesthesia vs., 221–222, 223–228, 229–231, 236, 236
germinal matrix, 357
gestation, prolongation using tocolytic therapy, 82–83
gestational age, fetal rights and, 368, 376
gestational hypertension, 303
GIFT (gamete intrafallopian transfer), 147
glomerular filtration rate (GFR), pregnancy-associated changes, 22, 54–55
glucocorticoids, fetal, 15
INDEX

glucose metabolism, fetal, 114  
lactate and, 115

gonads, development, 5  
Gregory, John, 376–377

growth, fetal see fetal growth  
growth hormone, 15

growth restriction, intrauterine see  
intrauterine growth restriction (IUGR)

H  
hair, fetal, effect on fetal pulse oximetry readings, 125

Haldane effect, 26

halogenated volatile anesthetics  
effect on assisted reproduction techniques and early pregnancy, 152–153  
see also volatile anesthetic agents; specific anesthetic agents

halothane  
developmental effects, 150, 159  
effect on assisted reproduction techniques and early pregnancy, 152–153  
neonatal effects, 218

“head sparing,” 12, 100

heart  
congenital disorders see congenital heart defects  
development, 5  
pregnancy-associated structural changes, 20

heart murmurs, pregnant women, 20

heart rate  
fetal see fetal heart rate  
neonatal, assessment, 68

heat loss, fetal, 278, 279

heat production–heat loss imbalance, epidural-related fever, 280

HELLP syndrome, 303, 305, 306

Mississippi classification, 305, 305

hematologic system, pregnancy-associated changes, 22

hemodynamic changes, preeclampsia, 303–304

hemodynamic monitoring, pregnant trauma patients, 331

hemoglobin  
fetal see fetal hemoglobin  
natal levels, 22, 114  
nonal levels, 25

hemorrhage  
fetal, 347

intracranial, neonates, 359–360

hepatic circulation, fetal, 35, 41

Hering–Breuer reflex, 67

hernia, congenital diaphragmatic see  
congenital diaphragmatic hernia (CDH)

herniation, hindbrain, 8, 9

heroin abuse, 165

heroin withdrawal, 168

high spinal block, 290–291

hindbrain herniation, 8, 9

holoprosencephaly, alobar, 91

hormones, fetal, 14–15

hospital assessment, maternal trauma patients, 330

human epidemiological studies, anesthesia-induced developmental neuroapoptosis, 205–206

hydralazine, 304

hydronephrosis, fetal, 7–8, 92

hydrophilic drugs, placental transfer, 55

hyperoxia-induced fetal lipid peroxidation, 246, 248

hypertensive disease, maternal, 4, 12

treatment, 304–305  
see also preeclampsia

hypertensive response to laryngoscopy/tracheal intubation, pharmacological attenuation, 240, 240–241, 241

hyperthermia  
malignant, 289

maternal see maternal hyperthermia

hypnotics, effect on fetal development, 157, 161

hypoplastic left heart syndrome (HLHS), 179, 358  
nonal management, 358–359

hypotension, maternal see maternal hypotension

hypothalamus, role in epidural-related fever, 280–281

hypothermia  
malignant, 289

therapeutic see therapeutic hypothermia

hypovolemia, maternal, 329, 331  
management, 331

hypoxemia  
fetal see fetal hypoxemia  
natal, 12

hypoxia  
fetal see fetal hypoxia  
intrapartum see intrapartum hypoxia

neonatal response, 66

hypoxic ischemic encephalopathy (HIE), 129, 130, 287, 290, 360

neonatal management, 360

I  
identical twins, 297

illness severity scores, 131–132, 132

imaging  
diagnostic, pregnant trauma patients, 332

MRI see magnetic resonance imaging (MRI)

ultrasound see ultrasonography

incompetency, legal in pregnancy, 369, 370, 371

indirect measurement, 76

indivisibly linked theory, 368

infections, maternal, 12

inflammation, epidural-related fever and, 281

informed consent, 369, 377

inhalational anesthetics  
effect on assisted reproduction techniques and early pregnancy, 152–153

effect on fetal development, 150, 157, 159

effect on fetus/neonate, 218

malignant hyperthermia, 289

occupational exposure see occupational exposure, inhalational anesthetics  
see also general anesthesia; specific anesthetic agents

inhibitors of apoptosis (IAPs), 193

Injury Severity Score (ISS), 328

insulin, fetal, 15

insulin-like growth factors (IGFs), 15

interleukin-6 (IL-6), epidural-related fever and, 281

internal consistency reliability, 78

intrarater reliability, 77

390
independent correlation coefficient (ICC), 78
intracranial hemorrhage, neonatal, 339–360
intralipid, 290
intrapartum hypoxia
prediction of abnormal outcome, 119, 119–120 prevention, 119
see also fetal hypoxia
intrapartum management
twins, 301
see also labor analgesia
intrarater reliability, 77
intrathecal analgesia/anesthesia see spinal analgesia/anesthesia
intrauterine fetal procedures see fetal surgical interventions
intrauterine growth see fetal growth
intrauterine growth restriction (IUGR), 10, 12, 308–309, 309 asymmetric, 10, 12 early ultrasound screening, 94 fetal factors, 14–15 “head sparing,” 12, 100 long-term effects, 16 magnetic resonance imaging, 99–100 maternal factors, 12, 14 placental factors, 14 symmetric, 10 twins, 299 intravenous anesthetic agents
developmental effects, 150, 157, 159–161 neonatal effects, 218 see also general anesthesia; specific anesthetic agents
intravenous fluid administration
effect on fetal pulse oximetry readings, 126 fetal resuscitation, 349 pregnant trauma patients, 331 regional anestheisa for cesarean delivery and, 237 intravenous medication, maternal resuscitation, 338 intraventricular hemorrhage, neonatal, 359 intubation see tracheal intubation in utero surgery see fetal surgical interventions in vitro fertilization (IVF), 147 ionizing radiation, fetal exposure, 332 ion trapping, 57, 57 ischemia–reperfusion, oxygen radical formation, 248 isoflurane
developmental effects, 150, 153 neonatal effects, 218 8-isoprostanate, 246, 248 Israel, forced medical intervention law, 367
J
justice, 365, 368
K
ketamine
developmental effects, 150, 160 effect on assisted reproduction techniques and early pregnancy, 151–152 neonatal effects, 218 kidneys
development, 5 preeclampsia-associated complications, 307–308 pregnancy-associated vascular changes, 22, 329
L
labelol, 304, 305 labor
acid–base balance during, 116, 117 fetal surveillance, 50, 82, 116, 118 maternal cardiovascular changes, 22 see also parturition
labor analgesia, 263 breastfeeding effects see under breastfeeding fetal effects see labor analgesia, fetal effects neuraxial see neuraxial analgesia/anesthesia placental drug transfer, 263–264, 264 systemic see systemic labor analgesia labor analgesia, fetal effects, 263–268 direct effects, 264–265 early vs. late regional analgesia, 272, 273, 274 fetal pulse oximetry readings, 126, 127 indirect effects, 265–266 systemic vs. neuraxial analgesia, 266–268 labor pain, fetal effects, 265 lactate levels fetal, determination, 115–116, 116 umbilical cord blood, 120–121 laryngeal mask airway (LMA)
duty of care to fetus, 369 forced medical intervention, 366–367 maternal competency and, 369–372 maternal–fetal challenges, 367–369, 369b, 376 leg elevation, after spinal anesthesia, 257 lidocaine effect on fetal development, 161 toxicity, 290 lipemil emulsion, treatment of local anesthetic toxicity, 290 liperoxidation, fetal, hyperoxia-induced, 246, 248 lipophilic drugs placental metabolism, 56 placental transfer, 55 lithium, neuroprotective effects, 195 liver
development, 6 fetal see fetal liver
INDEX

local anesthetics
effect on assisted reproduction
techniques and early
pregnancy, 149, 151
effect on fetal development, 157,
161–162
placental transfer, 264
toxicity, 264, 290
see also neuraxial analgesia/
anesthesia; specific anesthetic
agents
low birthweight, long-term effects, 16
lung(s)
development, 5
function, pregnancy-associated
changes, 23
functional residual capacity,
establishment of, 63–64
lung fluid, 63
lung fluid clearance, 63
reduced, cesarean delivery,
216–217
M
macrosomia, 15
magnetic resonance imaging (MRI),
97–102, 332
blood-oxygen-level-dependent
(BOLD) functional MRI, 101
diffusion tensor imaging, 100
diffusion-weighted imaging, 100
fetal see fetal magnetic resonance
imaging
placental, 101, 101–102
safety in pregnancy, 102, 332
magnetic resonance (MR)
spectroscopy
fetal, 100–101
placental, 102
malignant hyperthermia, 289
malondialdehyde (MDA), 246, 248
marijuana (cannabis)
maternal abuse, 167, 169
withdrawal, symptoms and
treatment, 168
maternal adaptations to pregnancy,
19–24, 39–41, 158, 329
anesthesia and, 158
cardiovascular changes see
cardiovascular changes,
maternal
pharmacokinetics and, 53–55
renal changes, 22, 329
respiratory changes, 23–24, 39,
158, 329
trauma response and, 329
twin gestation, 298
uterine changes, 23, 329
maternal anesthesia see anesthesia
maternal anesthetic complications,
285–291
anaphylaxis, 289
causes, 286
drug errors, 286, 291
high/total blocks, 290–291
inadequate airway management in
general anesthesia, 288–289
local anesthetic toxicity, 290
malignant hyperthermia, 289
maternal death, 288
mechanism of fetal harm, 286
see also fetal hypoxia
regional anesthesia, 286,
290–291
maternal autonomy
fetal beneficence and, 365–372, 376
respect for, 375
maternal blood
affinity for respiratory gases,
25–26, 26
hemoglobin levels, 22, 114
pH, placental drug transfer and,
57, 57
maternal blood pressure
cardiac output vs., 238
effects on uterine and umbilical
blood flow, 29
pregnancy-associated changes,
20–21
maternal blood pressure control,
physiologic considerations,
235–236
maternal blood pressure control, fetal
effects, 235–241
general anesthesia, 239–241
regional anesthesia, 236–239
maternal complications
anesthesia see maternal anesthetic
complications
EXIT procedure, 189
preeclampsia-associated see under
preeclampsia
twin gestation, 298
see also specific complications
maternal death, 288
maternal factors
fetal oxygenation abnormalities,
43–44
intrauterine growth restriction, 12,
14
maternal–fetal research ethics,
377–379
maternal fever see maternal pyrexia
maternal hypertension, 4, 12
treatment, 304–305
see also preeclampsia
maternal hyperthermia, 12
epidural analgesia association see
epidural-related fever
fetal consequences, 279, 279–280
see also maternal pyrexia
maternal hypotension, 118, 186,
251, 253
fetal risks, 236–237
general anesthesia-associated, 240
neuraxial anesthesia-associated,
118, 220, 236–237, 251, 253
positioning during neuraxial
anesthesia and, 253, 254, 255,
256, 257
maternal hypothermia, 289
maternal oxygen administration,
244–249, 321
fetal effects, 244–249
adverse, 246, 248
fetal oxygenation, 29–30,
245–246
fetal pulse oximetry readings,
126
neonatal condition, 246, 247
fetal resuscitation, 349–350
maternal considerations, 248–249
methods, 244–245
nasal cannulae, 244
oxygen masks, 244–245
transfer of oxygen to fetus,
245–246
maternal pharmacokinetics, 53–55
study considerations, 58–59, 59
maternal position
cesarean delivery see cesarean
delivery, maternal position
effect on fetal pulse oximetry
readings, 126
fetal resuscitation, 348
maternal resuscitation, 335–336
maternal posture, aortocaval
compression and, 252
maternal pyrexia, 118
epidural-related see epidural-related fever
fetal consequences, 279–280
malignant hyperthermia, 289
neural tube defects and, 289
maternal resuscitation, 241, 335–339
advanced life support, 336, 338
basic life support, 335–338, 336
guidelines, 335, 336
treatment after return of spontaneous circulation, 339
maternal salvage
perimortem cesarean delivery for, 340
see also maternal resuscitation
maternal trauma, 327–333
basic principles, 329–330
epidemiology, 327–328
fetal outcome, 328
fetal physiology and, 329–330
management see maternal trauma, management
maternal outcome, 328
maternal physiology and response to, 329
mechanism and etiology of injury, 328
prevention, 328–329
uterine physiology and response to, 329–330
maternal trauma, management, 330–332
cesarean delivery, 331–332
see also perimortem cesarean delivery
clinical practice, 330–331
diagnostic imaging, 332
fluid resuscitation, 331
hemodynamic monitoring, 331
initial hospital assessment, 330
intubation and ventilation, 330–331
pre-hospital, 330
tocolytic agents, 331
vasopressors, 331
see also maternal resuscitation
MDA (malondialdehyde), 246, 248
measurement, 75–83
approaches, 75–76
direct, 75–76
effects of error, 77, 77, 78
indirect, 76
reliability see reliability
surrogate endpoints, 80–82
true score theory, 76
validity see validity
meconium-stained amniotic fluid (MSAF), resuscitation of non-vigorous infant with, 336–357
medical ethics
definition, 374
see also ethics
medication
intravenous, maternal resuscitation, 338
see also entries beginning drug
megacystis, 91
meningocoele, 8
mesoderm, 7
metabolic acidemia, fetal, 114–116
methadone, 165
withdrawal, 168
metoclopramide, effect on assisted reproduction techniques and early pregnancy, 153
midazolam, 91
midnamic acidemia, fetal, 114–116
methadone, 165
withdrawal, 168
metoclopramide, effect on assisted reproduction techniques and early pregnancy, 153
microcephaly, 91
myelocele, 8
myelomeningocele (MMC), 8, 178
neonatal intervention, 178
neonatal management, 359
N
NACS (neurologic and adaptive capacity score), 133–134
nasal cannulae, maternal oxygen administration, 244
neck-coolers, epidural-related fever management, 282, 282
neonatal abstinence syndrome (NAS), 134, 165
assessment, 134, 135
neonatal assessment, 129–135, 316
acid–base balance, 129–131
cardio-respiratory, 67–69
see also Apgar score
illness severity scores, 131–132, 132
neonatal abstinence syndrome, 134, 135
neurobehavioral see neonatal neurobehavioral scores
neurological, 133–134
pain, 134, 134
prediction of neonatal outcome and, 129–134, 316
neonatal breathing, 63–67
assessment, 68
characteristics of postpartum breathing, 65–66
establishing functional residual capacity, 63–64
initiation, 64–65, 65
neonatal resuscitation, 354–355
periodic breathing, 66
respiratory reflexes, 66–67
neonatal circulation
neonatal resuscitation, 355–356
transition from fetal circulation, 67
neonatal complications
EXIT procedure, 189
management, 359–360
see also neonatal resuscitation
neonatal emergencies, 357–360
congenital anomalies, 357–359
neonatal complications, 359–360
simulation, 360
see also neonatal resuscitation
neonatal morbidity, anesthesia-related, cesarean delivery, 221
neonatal mortality, anesthesia-related, cesarean delivery, 221, 222
neonatal neurobehavioral scores, 133–134
general vs. regional anesthesia for cesarean delivery, 226–228, 230
systemic vs. neuraxial labor analgesia, 267–268
<table>
<thead>
<tr>
<th>Nitrous oxide exposure</th>
<th>Operating rooms, scavenging systems, 141, 142, 144</th>
</tr>
</thead>
<tbody>
<tr>
<td>Animal studies, 144, 159</td>
<td>Operation on placental support (OOPS), 184</td>
</tr>
<tr>
<td>Effect on assisted reproduction</td>
<td>Oxygen uptake</td>
</tr>
<tr>
<td>Techniques and early pregnancy, 152</td>
<td>Fetal, 25, 26, 26, 27</td>
</tr>
<tr>
<td>Effect on fetal blood flow, 265</td>
<td>See also fetal oxygenation</td>
</tr>
<tr>
<td>Effect on fetal development, 150, 159</td>
<td>P</td>
</tr>
<tr>
<td>Occupational, 142–143</td>
<td>Pain</td>
</tr>
<tr>
<td>Placental transfer, 264, 264</td>
<td>External cephalic version-associated, 212</td>
</tr>
<tr>
<td>NMDA (N-methyl-D-aspartate) receptors, anesthesia-induced developmental neuroapoptosis and, 193–194, 200</td>
<td>Fetal, 174–175</td>
</tr>
<tr>
<td>Non-human primate studies, anesthesia-induced developmental neuroapoptosis, 201, 204–205</td>
<td>Labor, fetal effects, 265</td>
</tr>
<tr>
<td>Non-identical twins, 297</td>
<td>Pain assessment, neonatal, 134, 134</td>
</tr>
<tr>
<td>Non-maleficence, 365, 375</td>
<td>Pancreas, development, 6</td>
</tr>
<tr>
<td>Non-obstetric surgery, anesthesia for, 156</td>
<td>Paradoxical reflex of Head, 67</td>
</tr>
<tr>
<td>Developmental effects see fetal development, effect of anesthetic drugs</td>
<td>Parturition</td>
</tr>
<tr>
<td>Non-steroidal anti-inflammatory agents (NSAIDs), effect on assisted reproduction techniques and early pregnancy, 152</td>
<td>Anesthetic management of substance-abusing parturients, 170</td>
</tr>
<tr>
<td>Non-stress tests (NSTs), 44, 50</td>
<td>Twins, maternal complications, 298</td>
</tr>
<tr>
<td>“Not-one-but-not-two” model, 368</td>
<td>See Also labor</td>
</tr>
<tr>
<td>Nuchal translucency (NT) thickness, 90</td>
<td>Organic hydroperoxides (OHP), 246</td>
</tr>
<tr>
<td>Nutrition, maternal, 12</td>
<td>Organogenesis, 5–6, 7, 9</td>
</tr>
</tbody>
</table>

O

Occupational exposure, inhalational anesthetics, 141–145
Animal studies, 144
Associated pregnancy complications, 142, 143
Developmental outcome, 143
General considerations, 141–142
Nitrous oxide, 142–143
Occupational exposure, sterilizing agents, 144
Omphalocele, neonatal management, 359
Oocytes, transvaginal retrieval, 147, 148
Open mid-gestation fetal surgery, 184

P

Pain
External cephalic version-associated, 212
Fetal, 174–175
Labor, fetal effects, 265
Pain assessment, neonatal, 134, 134
Pancreas, development, 6
Paradoxical reflex of Head, 67
Parturition
Anesthetic management of substance-abusing parturients, 170
Twins, maternal complications, 298
See Also labor
Pelvis, magnetic resonance imaging of fetal anomalies, 99
Percutaneous fetal procedures, 173–174
Perimortem cesarean delivery, 288, 332, 339–341
For fetal salvage, 340, 341
For maternal survival, 340
Prerequisites for performance of, 341
Technique, 340–341
Periodic breathing, 66
Peripartum cardiomyopathy (PPCM), 307
Peripartum hyperthermia, 280
Peripheral resistance, pregnancy-associated changes, 20–21
P-glycoprotein, placental, 55, 263–264
pH
Placental drug transfer and, 56–58, 57
Umbilical artery, 82, 117, 120
See Also acid-base balance
Pharmacokinetics, 53–60
Anesthetic agents See anesthetic agents, pharmacokinetics
Fetal See fetal pharmacokinetics
Maternal See maternal pharmacokinetics
Placental See placental drug transfer
Study considerations, 58–59, 59
phenylephrine, 186, 319, 321
regional anesthesia for cesarean delivery and, 237–238, 238, 239
physiology
fetal see fetal physiology
maternal adaptations to pregnancy see maternal adaptations to pregnancy
Pierre–Robin sequence, 357–358
pituitary, development, 6
pKa, placental drug transfer and, 57
placenta, 14, 23
blood flow, 27, 32, 55
see also umbilical blood flow; uterine blood flow; uteroplacental circulation
formation see placentation
magnetic resonance imaging, 101, 101–102
respiratory gas exchange, 25–30, 41
see also fetal oxygenation
role in fetal growth, 14
secretion of bioactive substances, 39
placental abruption, 308
placental drug transfer, 55, 263–264, 264
study considerations, 59, 59
placental drug transfer, factors influencing, 55–58
acid–base equilibrium effect, 56–58, 57
maternal and fetal protein binding, 56
mechanism of transfer across placenta, 55
metabolism and binding by placenta, 56
placental growth factor, 23
placental insufficiency, 10, 14, 44, 118
risk factors, 44, 44
placental malformation, twin gestation, 299
placentaion, 4, 23
impaired, 89
early screening, 93–94
plasma proteins, drug-binding, 54
plasma volume expansion, during pregnancy, 21, 39
drug distribution and, 54
platelets, pregnancy-associated changes, 22
pleural effusion, congenital, 358
pneumothorax, neonatal, 359
polyhydramnios, 92
position
fetal, early vs. late labor analgesia, 272, 274
maternal see maternal position
positive pressure ventilation (PPV)
effect on uteroplacental blood flow, 219
neonatal resuscitation, 354, 355
postmortem cesarean delivery, 288
postnatal adaptations, 63–69
cardio-respiratory assessment, 67–69
see also Apgar score
cardiovascular system, 67
respiratory system see neonatal breathing
postpartum breathing characteristics, 65–66
see also neonatal breathing
postpartum maternal management, EXIT procedure, 187, 189
PPV see positive pressure ventilation (PPV)
preeclampsia, 4, 12, 14, 23, 303–311
cardiopulmonary complications, 306–307
early screening, 93–94
effects of anesthesia, 231, 309–311
general anesthesia, 311
regional anesthesia, 231, 239, 309–311
gastrointestinal complications, 305, 305, 305–306, 306
hemodynamic changes, 303–304
intrauterine growth restriction and, 308–309
mild, 303, 304
neurologic complications, 307
placental abruption and, 308
renal complications, 307–308
severe, 303, 304
treatment of hypertension, 304–305
pregnancy complications
anesthetics-related, 142, 143
twin gestation, 298
see also fetal complications; maternal complications; specific complications
pregnant women
competency, legal 369–372
environmental exposure to anesthetic agents see occupational exposure, inhalational anesthetics
fetal rights and, 367–368, 376
forced medical intervention, 366–367
physiological adaptations see maternal adaptations to pregnancy
safety of MRI, 102
substance abuse see substance abuse in pregnancy
see also entries beginning maternal
preoperative evaluation, EXIT procedure, 184
preoperative preparation, EXIT procedure, 184–185
presentation, twins, effect on route of delivery, 300–301
preterm birth
smoking-associated risk, 14
twins, 298–299
preterm neonates
brown adipose tissue deficiency, 10
hypoxic ischemic insults, 287
long-term effects of low birthweight, 16
oxygen saturation levels, 69
postpartum breathing, 65–66
resuscitation, 357
supplemental oxygen, 69, 357
primate studies, anesthesia-induced developmental neuroapoptosis, 201, 204–205
prognostic markers
fetus and, 82–83
surrogate endpoints vs., 80
programmed cell death see apoptosis
prolonged deceleration, 106, 108
propofol, effects
on assisted reproduction techniques and early pregnancy, 152
on fetal development, 160
pseudosinusoidal pattern, 111
psychometric tools, 76
pulmonary circulation, fetal, 35
pulmonary edema, preeclampsia-associated, 306–307, 308
INDEX

pulmonary stretch receptors, respiratory reflexes arising from, 67
pulsatility index (PI), uterine artery, 40, 41, 49, 49, 93
pulse oximetry fetal see fetal pulse oximetry neonatal, 355
pyrexia, maternal see maternal pyrexia
R
radiation exposure, in pregnancy, 332
radiographs, chest, pregnancy-associated changes, 20
random error, 77, 77
randomized trials, maternal–fetal research ethics, 378
randomized trials, maternal–fetal research ethics, 378
randomized trials, maternal–fetal research ethics, 378
radiographs, chest, pregnancy-associated changes, 20
radiographs, chest, pregnancy-associated changes, 20
random error, 77, 77
randomized trials, maternal–fetal research ethics, 378
red blood cells, pregnancy-associated changes, 22
reflexes, respiratory, neonatal, 66–67
regional analgesia/anesthesia see neuraxial analgesia/anesthesia
reliability, 76–78
estimates, 77–78
internal consistency, 78
intrarater, 77
intrarater, 77
intrarater, 77
intrarater, 77
test–retest, 77–78
validity and, 78–79, 79
remifentanil attenuation of stress response to laryngoscopy/tracheal intubation, 240–241, 241
effect on fetal heart rate, 265
labor analgesia, 265
placental transfer, 264
renal circulation, pregnancy-associated changes, 22, 329
renal complications, preeclampsia, 307–308
renal vascular resistance (RVR), pregnancy-associated changes, 22
renin–angiotensin–aldosterone system, 19, 21
research ethics, 376–379
components, 376–377
maternal–fetal, 377–379
respiratory acidemia, fetal, 114–116
respiratory alkalosis, fetal, 24
respiratory gases
affinity of fetal and maternal blood for, 25–26
carbon dioxide, placental exchange, 24, 25, 26
oxygen see entries beginning oxygen
respiratory gas exchange
fetal physiology, 114
placental, 25–30, 41 see also fetal oxygenation
respiratory rate, neonatal, assessment, 68
respiratory reflexes, neonatal, 66–67
respiratory system
maternal adaptations to pregnancy, 23–24, 39, 158, 329
postnatal adaptations see neonatal breathing see also lung(s)
resuscitation
fetal see fetal resuscitation
maternal see maternal resuscitation
neonatal see neonatal resuscitation
route of delivery, twins, 300
S
sacroccygceal teratoma, 8, 99
fetal interventions, 178
scavenging systems, operating rooms, 141, 142, 144
scheduled cesarean delivery, 288 see also cesarean delivery
score for neonatal acute physiology (SNAP), 131–132, 132
score for neonatal acute physiology with perinatal extension (SNAPPE), 131–132, 132
sedatives, effect on fetal development, 157, 161
sentinel events, 347
separate entity theory, 368
sex steroids, uteroplacental circulation and, 23
Simpson, James Young, 315
simulation, neonatal emergencies, 360
single entity theory, 368
sinusoidal pattern, 111
sitting position, neuraxial anesthesia, 252–253, 254, 255, 256, 257
skin temperature, fetal, 279
small for gestational age (SGA), 10, 94
smoking, 12, 14, 169 see also tobacco
SNAP (score for neonatal acute physiology), 131–132, 132
SNAPPE (score for neonatal acute physiology with perinatal extension), 131–132, 132
solvents, maternal abuse, 167, 169–170
sonography, heart, pregnancy-associated changes, 20
spastic cerebral palsy, 130 see also cerebral palsy
spectroscopy, magnetic resonance see magnetic resonance (MR) spectroscopy
spina bifida, 8
open, first-trimester screening, 93 see also myelomeningocele (MMC)
spinal analgesia/anesthesia external cephalic version, 211
maternal complications, 290–291
maternal positioning during cesarean delivery, 253, 254, 255, 256–257
preeclamptic women, 310, 311
urgent cesarean delivery for fetal distress, 317–318, 319, 320, 321
see also neuraxial analgesia/anesthesia
spinal analgesia/anesthesia, fetal/neonatal effects, 220
fetal pulse oximetry readings, 126, 127
general anesthesia vs., 236, 236 see also neuraxial analgesia/anesthesia, fetal/neonatal effects
spinal cord defects see neural tube defects
spleen, development, 6
spontaneous abortions, anesthetic-related, 142, 143
sterilizing agents, exposure during pregnancy, 144
strong ion difference, 116
subgaleal hemorrhage, neonatal, 359–360
INDEX

substance abuse in pregnancy, 165–170
amphetamine, 166, 169
anesthetic management of substance-abusing parturient, 170
cocaine, 166, 170
ethanol, 14, 166, 170
marijuana (cannabis), 167, 169
opioids, 165, 166
signs and symptoms, 166–167
solvents, 167, 169–170
tobacco, 12, 14, 167, 169
withdrawal symptoms and treatment, 168
supine position
adverse effects, 251, 252
aortocaval compression and, 252
neuraxial anaesthesia and, 253, 254, 255, 256, 257
supplemental oxygen
maternal see maternal oxygen administration neonatal resuscitation, 355
preterm infants, 69, 357
surfactant, 64
surgery
in early pregnancy, 147–148
fetal see fetal surgical interventions
neonatal, preoperative MRI, 99
surgical incision
EXIT procedure, 186–187
uterine, effects on fetus, 217
surrogate endpoints, 80–83
choosing, 80–82, 81
definition, 80
fetus and, 82–83
prognostic markers vs., 80
symmetric intrauterine growth restriction, 10
synaptogenesis, 192, 201
syncytiotrophoblast, 3
systematic error, 77, 78
systemic labor analgesia, 263
fetal effects, 263, 266
neuraxial analgesia vs., 266–268
systemic vascular resistance (SVR)
preeclamptic women, 303–304
pregnancy-associated changes, 20
systolic ejection murmurs, pregnant women, 20

tachycardia, fetal see fetal tachycardia
tachysystole, 109, 112, 347
TAPVR (total anomalous pulmonary venous return), 358, 359
temperature, fetal skin, 279
teratogenesis, 156–157
teratogens
definition, 156
periods of vulnerability to exposure, 3, 4, 156
teratomas, sacrococcygeal see sacrococcygeal teratoma
terbutaline, 346, 348, 349
testis, development, 5
test–retest reliability, 77–78
thalidomide, 157
therapeutic hypothermia
hypoxic ischemic encephalopathy management, 360
post-resuscitation in pregnant women, 339
thermal homeostasis, 280
epidural-related fever and, 280–281
thiopental, effects on assisted reproduction techniques and early pregnancy, 152
on fetal development, 159–160
neonatal, 218
thoracentesis, neonatal, 358, 359
thorax, magnetic resonance imaging of fetal anomalies, 99
thymus, development, 6
thyroxin, fetal, 15
timing of delivery, twins, 300
tobacco
maternal abuse, 12, 14, 167, 169
withdrawal, 168
tocodynamometry, 109
tocolytic therapy
fetal resuscitation, 348
maternal trauma management, 331
prolongation of gestation, 82–83
toluene, maternal abuse, 169–170
total anomalous pulmonary venous return (TAPVR), 358, 359
total spinal block, 290–291
toxicity, local anesthetic, 264, 290
tracheal intubation
maternal resuscitation, 336, 338
neonatal resuscitation, 354, 354
pregnant trauma patients, 330–331
transposition of the great arteries (TGA), neonatal management, 358–359
transvaginal oocyte retrieval, 147, 148
trauma, 327
maternal see maternal trauma
trisomy 21, 90
trophoblasts, 3, 40
ture score theory, 76
twin reversed arterial perfusion (TRAP), fetal intervention, 177–178
twins, 297–301
aneuploidy screening, 90–91
complications see twins, complications
delivery, 300–301
fetal growth, 12, 14
incidence, 297
intrapartum management, 301
maternal physiology, 298
presentation, effect on route of delivery, 300–301
singleton vs., 297
types, 297
twins, complications, 298–300
fetal, 298–299
maternal, 298
unique to monochorionic twins, 299–300
twin–twin transfusion syndrome, 9, 299–300
fetal intervention, 9, 177, 177

U
UK, forced medical intervention law, 366
ultrasonography, 89–94
fetal see fetal ultrasound screening
impaired placentation, 93–94
see also Doppler ultrasound evaluation
umbilical artery
compression, 44
Doppler ultrasound evaluation, 36
pH, 82, 117, 120
see also umbilical cord blood acid–base values
umbilical blood flow, 27, 32
effect of blood pressure, 29
restriction, effect on fetal oxygenation, 28–29
umbilical cord blood acid–base values, 116, 117
analysis at delivery, 121
clinical interpretation, 120
early vs. late initiation of neuraxial labor analgesia, 274, 274–275
umbilical cord blood lactate levels analysis at delivery, 121
clinical interpretation, 120–121
umbilical cord blood sampling, pharmacokinetic studies, 59, 59
umbilical cord compression, 44, 110, 118
umbilical cord prolapse, 347, 349
umbilical vein, 33, 41
catheterization, 356
compression, 44
Doppler ultrasound evaluation, 36
umbilical vein blood, 32
oxygen saturation, 32, 33
United States of America (USA)
Food and Drug Administration, category ratings of drugs during pregnancy, 157, 157, 157b
forced medical intervention law, 366
urgent cesarean delivery, 288
see also cesarean delivery
urgent cesarean delivery, fetal indication
anesthesia for see fetal distress, anesthesia for
degree of urgency, 316–317
management guidelines, 320, 321
uridine diphosphateglucuronosyltransferase (UGT)
fetal, 58
maternal, 54
placental, 56
urinary tract obstruction (UTO), 176
fetal intervention, 176–177
uterine activity monitoring (tocodynamometry), 109
uterine artery
blood flow, 27
see also uterine blood flow
diastolic notch, 40, 40, 49
Doppler ultrasound evaluation, 40, 40, 49, 83, 93
pulsatility index, 40, 41, 49, 49, 93
uterine blood flow, 27
changes, effect on fetal oxygenation, 27–28
effect of blood pressure, 29
insufficient, 110–111
pregnancy-associated changes, 23, 329
at term, 285
see also uteroplacental circulation
uterine contractions, effect on fetal pulse oximetry readings, 125
uterine incision, effects on fetus, 217
uterine tachysystole, 109, 112, 347
uteroplacental circulation, 23, 32
effect of anesthetic drugs on blood flow, 219
effect of maternal cardiac arrest, 337
effect of ventilation on blood flow, 219
maternal blood pressure and, 235
MRI assessment, 101–102
physiological changes of relevance to anesthesiologist, 316
ultrasound assessment, 40, 40, 49, 83, 93–94
uterine contractions and, 330
see also uterine artery; uterine blood flow
uteroplacental insufficiency (UBF), 110–111
uterus, pregnancy-associated vascular changes, 23, 329
vascular endothelial growth factor (VEGF), placental, 23
vascular resistance, systemic see systemic vascular resistance (SVR)
vasopressors
cesarean delivery for fetal distress and, 319
fetal/neonatal effects, 220
maternal trauma management, 331
regional anesthesia for cesarean delivery and, 237–238, 238, 239, 319
venous structure and function, pregnancy-associated changes, 21
ventilation
effect on uteroplacental blood flow, 219
maternal resuscitation, 336, 338
neonatal resuscitation, 354–355
pregnant trauma patients, 330–331
ventriculomegaly, 91, 98
volatile anesthetic agents
effect on assisted reproduction techniques and early pregnancy, 152–153
effect on fetal development, 150, 157, 159
see also inhalational anesthetics; specific anesthetic agents
volume expansion
maternal hypertension treatment, 304
neonatal resuscitation, 356
volumetry, fetal organs, 99–100
W
white blood cells, pregnancy-associated changes, 22
wrapping, after spinal anesthesia, 257
X
xenon, neuroprotective effects, 194–195
Z
zygote, 3